Abstract

Background: The neutrophils (PMN) are our main blood cells to combat fungi, bacteria, and fibrin. For normal function, an activated PMN generates a certain concentration of reactive oxygen species (ROS). If the generated blood ROS concentration is too low, then fungi, bacteria or fibrin might threaten the life of the patient, and it could be of great medical interest to stimulate PMN by physiologic drugs. Granulocyte-Colony Stimulating Factor (G-CSF) is a cell hormone that increases the cell number of PMN and that stimulates the individual PMN. The blood ROS generation assay (BRGA) is an innovative physiologic test to monitor the ROS generation of PMN in blood. Here the ROS generating action of G-CSF on normal PMN is quantified. Material and Methods: 40 μl 0 - 10.3 ng/ml (final conc.) G-CSF (in 5% human albumin) in black Brand? 781608 high quality polystyrene F-microwells was incubated in triplicate with 125 μl Hanks’ balanced salt solution (HBSS; modified without phenol red) and 10 μl normal citrated blood. Immediately (BRGA) or after 60 min (BRGA-60-) 10 μl 5 mM luminol sodium salt in 0.9% NaCl and 10 μl 0 or 36 μg/ml zymosan A in 0.9% NaCl was added. The photons were counted within 0 - 318 min (37°C) in a photons-multiplying microtiter plate luminometer. At about 0.5 t-maxn (0.5 fold the time to normal maximum) the approx. SC200 of G-CSF was determined. Results and Discussion: The approx. SC200 of G-CSF on normal blood ROS generation was 0.2 μg/l (=20 IU/ml). In clinical situations where an increased blood ROS generation is pharmacologically required, few micrograms of G-CSF could be a sufficient dosage for an adult patient. The BRGA helps to find out the correct stimulating G-CSF dosage for each individual. An enhanced PMN function could favor a better clinical outcome in situations of wanted increase of the innate immunology or in cellular fibrinolysis. G-CSF plasma concentrations of 0.1 - 1 μg/l might favor singlet oxygen generation without immunosuppression or cell fragment-induced thrombin generation.

Highlights

  • The main cells of innate immunology are the phagocytes

  • In clinical situations where an increased blood reactive oxygen species (ROS) generation is pharmacologically required, few micrograms of granulocytecolony stimulating factor (G-CSF) could be a sufficient dosage for an adult patient

  • NaCl for control (Figure 1(b)) in black Brand® 781608 high quality polystyrene F-microwells were incubated in triplicate with μl Hanks’ balanced salt solution (HBSS; modified without phenol red) and 10 μl normal citrated blood. 10 μl 5 mM luminol sodium salt in 0.9% NaCl and 10 μl 36 μg/ml zymosan A in 0.9% NaCl were added

Read more

Summary

Introduction

The present study aimed to analyze the drug granulocytecolony stimulating factor (G-CSF) in the blood ROS generation assay (BRGA). [3] [4], an innovative test for whole blood ROS generation working with luminol-enhanced photons emission primarily by diluted whole blood PMN [5] [6]. The neutrophils (PMN) are our main blood cells to combat fungi, bacteria, and fibrin. An activated PMN generates a certain concentration of reactive oxygen species (ROS). ROS concentration is too low, fungi, bacteria or fibrin might threaten the life of the patient, and it could be of great medical interest to stimulate PMN by physiologic drugs. The blood ROS generation assay (BRGA) is an innovative physiologic test to monitor the ROS generation of PMN in blood.

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.